TherapeuticsMD (TXMD) Capital Expenditures (2011 - 2022)

TherapeuticsMD has reported Capital Expenditures for 12 years, with the latest figure at -$21000.0 in Q2 2022.

• For the quarter ending Q2 2022, Capital Expenditures fell 151.22% year-over-year to -$21000.0; the trailing twelve-month figure through Sep 2022 stood at $21000.0 (down 89.6% YoY), and the FY2021 full-year result was $34000.0, down 83.57% from the prior year.
• Capital Expenditures for Q2 2022 stood at -$21000.0, down from $42000.0 in the prior quarter.
• The five-year high for Capital Expenditures was $996909.0 in Q3 2019, with the low at -$70000.0 in Q3 2021.
• Historically, Capital Expenditures has averaged $172296.5 across 5 years, with a median of $41000.0 in 2021.
• Annual changes were most pronounced in 2019 — Capital Expenditures surged 4745.24% — and 2021, when it tumbled 638.46%.
• TherapeuticsMD's Capital Expenditures stood at $150745.0 in 2018, then soared by 139.2% to $360587.0 in 2019, then slumped by 53.41% to $168000.0 in 2020, then plunged by 141.67% to -$70000.0 in 2021, then surged by 70.0% to -$21000.0 in 2022.
• The last three Capital Expenditures figures came in at -$21000.0 (Q2 2022), $42000.0 (Q1 2022), and -$70000.0 (Q3 2021), per Business Quant data.